PHARMOSA BIOPHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.8 TWD | -0.43% |
|
-3.99% | -20.68% |
| Sales 2022 | - | Sales 2023 | 314.5 10.17K | Capitalization | 10.31B 333B |
|---|---|---|---|---|---|
| Net income 2022 | -267M -8.63B | Net income 2023 | 8M 259M | EV / Sales 2022 | - |
| Net cash position 2022 | 651M 21.06B | Net cash position 2023 | 830M 26.82B | EV / Sales 2023 | 30,156,637 x |
| P/E ratio 2022 |
-23.5
x | P/E ratio 2023 |
1,257
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.54% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.43% | ||
| 1 week | -3.99% | ||
| Current month | -8.64% | ||
| 1 month | -4.38% | ||
| 3 months | -30.89% | ||
| 6 months | -22.19% | ||
| Current year | -20.68% |
1 week
69.20
74.50
1 month
69.2082.70
Current year
64.10125.50
1 year
64.10162.00
3 years
31.00162.00
5 years
31.00162.00
10 years
31.00162.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pei Kan
CEO | Chief Executive Officer | - | 18-03-31 |
Shu Ping Yang
DFI | Director of Finance/CFO | - | 15-05-31 |
Ko Chieh Chen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Jen Wu
BRD | Director/Board Member | - | 22-01-09 |
Ko Jui Shih
BRD | Director/Board Member | - | 21-10-24 |
Wen Chang Chang
BRD | Director/Board Member | - | 22-01-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 69.8 | -0.43% | 133,384 |
| 24-06-13 | 70.1 | +0.86% | 109,281 |
| 24-06-12 | 69.5 | -0.71% | 121,555 |
| 24-06-11 | 70 | -3.71% | 319,880 |
| 24-06-07 | 72.7 | -1.36% | 211,752 |
End-of-day quote Taipei Exchange, June 13, 2024
More quotes
Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).
| 1st Jan change | Capi. | |
|---|---|---|
| -20.68% | 278M | |
| +40.80% | 53.67B | |
| -8.05% | 38.76B | |
| +35.79% | 38.86B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- 6875 Stock
